SANTA ANA, Calif., June 29 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) today announced that under the terms of the indenture governing its 3 1/2% Convertible Senior Subordinated Notes Due 2023 (the "Notes"), each holder of Notes may, at such holder's option, convert its Notes into shares of AMO common stock, par value $0.01 per share, during the quarter ending September 30, 2005, at a conversion rate of 48.6914 shares per $1,000 principal amount of Notes. As of June 28, 2005, AMO had approximately $5.6 million in principal amount of Notes outstanding, and shares issuable upon conversion of the Notes have already been included in AMO's calculation of weighted average diluted shares outstanding.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO)

Under the terms of the indenture, each holder has the right to convert such holder's Notes during any fiscal quarter if the closing sale price of AMO's common stock for at least 20 trading days in the 30 consecutive trading-day period ending on the last trading day of the immediately preceding fiscal quarter exceeds 120% of the conversion price in effect at the close of business on each of such 30 consecutive trading days. As of the close of business on June 24, 2005, the sale price of AMO's common stock had exceeded the conversion price of $20.538 per share by 120% for at least 20 trading days during the 30 consecutive trading-day period ending on June 24, 2005. As a result of this event, the Notes are convertible during the fiscal quarter ending on September 30, 2005. Upon conversion, AMO will have the right to deliver shares of common stock, cash or a combination of cash and shares of common stock. AMO will inform a converting holder of its election no later than two business days following such holder's conversion date. AMO will pay cash in lieu of issuing any fractional shares of common stock.

This press release is only a summary of certain provisions of the Notes and the indenture governing the Notes. A complete explanation of the conversion rights of holders of the Notes, as well as the procedures required to convert Notes, is set forth in the indenture. All holders are urged to review the conversion provisions contained in the Notes and the indenture in their entirety.

About Advanced Medical Optics (AMO)

AMO is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. Products in the ophthalmic surgical line include intraocular lenses, laser vision correction systems, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R), Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses, STAR S4(TM) laser vision correction system, WaveScan Wavefront(R) System, CustomVue(TM) procedure, Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the contact lens care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO is based in Santa Ana, California, and employs approximately 3,500 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Web site at http://www.amo-inc.com/.

Investor Contact: Erika Richmond (714) 247-8348 erika.richmond@amo-inc.com

CONTACT: Investors, Erika Richmond of Advanced Medical Optics, Inc.,
+1-714-247-8348, erika.richmond@amo-inc.com

Web site: http://www.amo-inc.com/